Search Results - "Steinberg, Edith"

Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 by Charvin, Delphine, Pomel, Vincent, Ortiz, Millan, Frauli, Mélanie, Scheffler, Sophie, Steinberg, Edith, Baron, Luc, Deshons, Laurène, Rudigier, Rachel, Thiarc, Delphine, Morice, Christophe, Manteau, Baptiste, Mayer, Stanislas, Graham, Danielle, Giethlen, Bruno, Brugger, Nadia, Hédou, Gaël, Conquet, François, Schann, Stephan

“…The metabotropic glutamate receptor 4 (mGluR4) is an emerging target for the treatment of Parkinson’s disease (PD). However, since the discovery of its…”
Get full text

Discovery of BI-9508, a Brain-Penetrant GPR88-Receptor-Agonist Tool Compound for In Vivo Mouse Studies by Fer, Mickael, Amalric, Camille, Arban, Roberto, Baron, Luc, Ben Hamida, Sami, Breh-Schlanser, Petra, Cui, Yunhai, Darcq, Emmanuel, Eickmeier, Christian, Faye, Vincent, Franchet, Christel, Frauli, Mélanie, Halter, Célia, Heyer, Marjorie, Hoenke, Christoph, Hoerer, Stefan, Hucke, Oliver T., Joseph, Christophe, Kieffer, Brigitte L., Lebrun, Louison, Lotz, Noémie, Mayer, Stanislas, Omrani, Azar, Recolet, Mandy, Schaeffer, Laurent, Schann, Stephan, Schlecker, Annette, Steinberg, Edith, Viloria, Mélanie, Würstle, Klaus, Young, Kyle, Zinser, Alexander, Montel, Florian, Klepp, Julian

“…Decreased activity and expression of the G-protein coupled receptor GPR88 is linked to many behavior-linked neurological disorders. Published preclinical GPR88…”
Get full text

Chemical Switch of a Metabotropic Glutamate Receptor 2 Silent Allosteric Modulator into Dual Metabotropic Glutamate Receptor 2/3 Negative/Positive Allosteric Modulators by Schann, Stephan, Mayer, Stanislas, Franchet, Christel, Frauli, Mélanie, Steinberg, Edith, Thomas, Mireille, Baron, Luc, Neuville, Pascal

“…Using an mGluR2 FRET-based binding assay, binders of the transmembrane region devoid of functional activity were identified. It is reported that slight…”
Get full text

Abstract 684: DT-9045, a novel PAR2 inhibitor with best-in-class properties that reduces resistance to both EGFR-targeting therapies and immunotherapy in oncology models by Brugat, Thibaut, Kadiri, Maleck, Aouad, Samya, Blayo, Anne-Laure, Rugeri, Baptiste, Mousson, Antoine, Janvier, Aurélie, Steinberg, Edith, Baron, Luc, Recolet, Mandy, Wirth, Xavier, Garcia-Leon, Maria Jesus, Ruet, Quentin, Semache, Meriem, Sabbagh, Laurent, Blanchard, Orphée, Franchet, Christel, Mayer, Stanislas, Stagg, John, Lenne, Nathalie, Schann, Stephan

“…Protease-activated receptor 2 (PAR2) is a promising therapeutic target in oncology and immuno-oncology. It is upregulated and associated with poor prognosis in…”
Get full text

Abstract 4961: Novel biased PAR2 inhibitors with best-in-class properties reduce resistance to both chemotherapy and immunotherapy in oncology models by Brugat, Thibaut, Bergami, Francesco, Rugeri, Baptiste, Janvier, Aurélie, Steinberg, Edith, Baron, Luc, Recolet, Mandy, Wirth, Xavier, Semache, Meriem, Mousson, Antoine, Dietsch, Camille, Ruet, Quentin, Blanchard, Orphée, Jacoberger-Foissac, Célia, Cousineau, Isabelle, Kadiri, Maleck, Blayo, Anne-Laure, Franchet, Christel, Mayer, Stanislas, Stagg, John, Lenne, Nathalie, Schann, Stephan

“…A large-scale meta-analysis has recently identified Protease-activated receptor 2 (PAR2) gene expression to be significantly associated with resistance to…”
Get full text